// App-Quantinova.ai

168 : Health-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 study.

Researchers

Presenter

  • Wasat Mansoor

Principal Investigators

  • Ken Kato

  • Jong-Mu Sun

  • Manish A. Shah

  • Peter C. Enzinger

  • Antoine Adenis

  • Toshihiko Doi

  • Takashi Kojima

  • Jean-Philippe Metges

  • Zhigang Li

  • Sung-Bae Kim

  • Byoung Chul Cho

  • Patrapim Sunpaweravong

  • MARIA ALSINA

  • Eray Goekkurt

  • Shailaja Suryawanshi

  • Josephine Norquist

  • Sukrut Shah

  • Lin Shen

Medical Centers

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Merck & Co., Inc., Kenilworth, NJ

  • National Cancer Center Hospital, Tokyo, Japan

  • Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea

  • Weill Cornell Medicine, New York, NY

  • Center for Esophageal and Gastric Cancer, Dana-Farber Cancer Institute, Boston, MA

  • IRMB Inserm U1183, Université de Montpellier, Montpellier, France

  • National Cancer Center Hospital, Tokyo, Japan

  • National Cancer Center, EPOC, Chiba, Japan

  • CHU Brest–Institut de Cancerologie et d’Hematologie ARPEGO Network, Brest, France

  • Shanghai Chest Hospital Esophageal Disease Center, Shanghai, China

  • Asan Medical Center, Seoul, South Korea

  • Gangnam Severance Hospital, Yonsei University Health System, Seoul, Korea

  • Prince of Songkla University, Hat Yai, Thailand.

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Hematology Oncology Practice Eppendorf, and University Cancer Center Hamburg, Hamburg, Germany

  • Peking University Cancer Hospital & Institute, Beijing, China

Locations

  • United Kingdom

  • United States

  • Japan

  • Republic of South Korea

  • France

  • China

  • Thailand

  • Spain

  • Germany

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Esophageal Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Cisplatin

  • Adrucil injection

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • NCT03189719

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved